IBDEI1LF ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28278,0)
 ;;=V18.61^^162^1794^19
 ;;^UTILITY(U,$J,358.3,28278,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28278,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,28278,1,5,0)
 ;;=5^Family H/O Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,28278,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,28279,0)
 ;;=V17.0^^162^1794^20
 ;;^UTILITY(U,$J,358.3,28279,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28279,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,28279,1,5,0)
 ;;=5^Family H/O Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,28279,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,28280,0)
 ;;=V19.4^^162^1794^21
 ;;^UTILITY(U,$J,358.3,28280,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28280,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,28280,1,5,0)
 ;;=5^Family H/O Skin Condition
 ;;^UTILITY(U,$J,358.3,28280,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,28281,0)
 ;;=V17.1^^162^1794^22
 ;;^UTILITY(U,$J,358.3,28281,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28281,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,28281,1,5,0)
 ;;=5^Family H/O Stroke (Cerebrovascular)
 ;;^UTILITY(U,$J,358.3,28281,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,28282,0)
 ;;=V16.8^^162^1794^18
 ;;^UTILITY(U,$J,358.3,28282,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28282,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,28282,1,5,0)
 ;;=5^Family H/O Other Specified Cancer
 ;;^UTILITY(U,$J,358.3,28282,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,28283,0)
 ;;=V11.1^^162^1794^23
 ;;^UTILITY(U,$J,358.3,28283,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28283,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,28283,1,5,0)
 ;;=5^Hx Of Affective Disorder
 ;;^UTILITY(U,$J,358.3,28283,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,28284,0)
 ;;=V15.89^^162^1794^46
 ;;^UTILITY(U,$J,358.3,28284,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28284,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,28284,1,5,0)
 ;;=5^Hx Of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,28284,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,28285,0)
 ;;=V11.3^^162^1794^24
 ;;^UTILITY(U,$J,358.3,28285,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28285,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,28285,1,5,0)
 ;;=5^Hx Of Alcoholism
 ;;^UTILITY(U,$J,358.3,28285,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,28286,0)
 ;;=V15.07^^162^1794^35
 ;;^UTILITY(U,$J,358.3,28286,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28286,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,28286,1,5,0)
 ;;=5^Hx Of Latex Allergy
 ;;^UTILITY(U,$J,358.3,28286,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,28287,0)
 ;;=V13.4^^162^1794^25
 ;;^UTILITY(U,$J,358.3,28287,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28287,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,28287,1,5,0)
 ;;=5^Hx Of Arthritis
 ;;^UTILITY(U,$J,358.3,28287,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,28288,0)
 ;;=V12.72^^162^1794^27
 ;;^UTILITY(U,$J,358.3,28288,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28288,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,28288,1,5,0)
 ;;=5^Hx Of Colon Polyps
 ;;^UTILITY(U,$J,358.3,28288,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,28289,0)
 ;;=V12.59^^162^1794^28
 ;;^UTILITY(U,$J,358.3,28289,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28289,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,28289,1,5,0)
 ;;=5^Hx Of Congestive Heart Failure
 ;;^UTILITY(U,$J,358.3,28289,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,28290,0)
 ;;=V45.81^^162^1794^29
 ;;^UTILITY(U,$J,358.3,28290,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28290,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,28290,1,5,0)
 ;;=5^Hx Of Coronary Bypass
 ;;^UTILITY(U,$J,358.3,28290,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,28291,0)
 ;;=V15.84^^162^1794^26
 ;;^UTILITY(U,$J,358.3,28291,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI1LF
